Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-CEL UVEC for Anal Fistulas
NCT04190862Phase 1Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of E-CEL UVEC in anal fistula (5 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Treatment-Emergent Adverse Events at 24 weeks. Started Jan 2020; status: active, not recruiting.
02
Drugs
E-CEL UVEC
03
Conditions
anal fistula
Beyond the preview
Go deeper on NCT04190862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190862.